Professional Documents
Culture Documents
doi:10.1093/annonc/mdi834
Follow-up 7. Yung WK, Albright RE, Olson J et al. A phase II study of temozolo-
mide vs. procarbazine in patients with glioblastoma multiforme at
. Follow-up consists of a clinical evaluation with particular first relapse. Br J Cancer 2000; 83: 588–593.
attention to neurological function, seizures or seizure 8. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy
equivalents and corticosteroid use. Patients should be with irinotecan plus carmustine in glioblastoma recurrent or progress-
tapered off steroid use as early as possible. ive after first-line temozolomide chemotherapy: a phase II study of
the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin
. Laboratory tests are not indicated unless patient is receiving
Oncol 2004; 22: 4727–4734.
chemotherapy (blood counts), corticosteroids (glucose) or
9. van den Bent M, Chinot OL, Cairncross JG. Recent developments in
anti-epileptic drugs (blood counts, liver function tests). the molecular characterization and treatment of oligodendroglial
tumors. Neuro-Oncol 2003; 5: 128– 138.
Note 10. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of
first-line chemotherapy with temozolomide in recurrent oligodendro-
Levels of Evidence [I –V] and Grades of Recommendation glial tumors: the European Organization for Research and Treatment
[A –D] as used by the American Society of Clinical Oncology of Cancer Brain Tumor Group Study 26 971. J Clin Oncol 2003; 21:
are given in square brackets. Statements without grading were 2525–2528.
considered justified standard clinical practice by the expert 11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response
authors and the ESMO faculty. criteria for phase II studies of supratentorial malignant glioma. J Clin
Oncol 1990; 8: 1277–1280.
12. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic fac-
tors in recurrent glioma patients enrolled onto phase II clinical trials.
Literature J Clin Oncol 1999; 17: 2572–2578.
1. DeAngelis LM. Medical Progress: Brain Tumors. N Engl J Med 13. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of
2001; 344: 114– 123. 416 patients with glioblastoma multiforme: prognosis, extent of resec-
2. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic tion, and survival. J Neurosurg 2001; 95: 190–198.
review and meta-analysis of individual patient data from 12 random-
ised trials. Lancet 2002; 359: 1011–1018. Coordinating authors for the ESMO Guidelines Task Force: R. Stupp1,
3. Medical Research Council Brain Tumor Working Party. Randomized N. Pavlidis2 & S. Jelic3
trial of procarbazine, lomustine and vincristine in the adjuvant treat-
1
ment of high-grade astrocytoma: A Medical Research Council trial. J Invited author, University Hospital (CHUV), Multidisciplinary Oncology
Clin Oncol 2001; 19: 509–518. Center, 1011 Lausanne, Switzerland; 2Assigned task force member,
4. Stupp R, Mason WP, van den Bent MJ et al. on behalf of the Euro- University of Ioannina, Dept. Medical Oncology, 45 110 Ioannina,
pean Organisation for Research and Treatment of Cancer Brain Greece; 3Assigned task force member, Institute of Oncology and
Tumor and Radiotherapy Groups and National Cancer Institute of Radiology of Serbia, Department of Medical Oncology, Pasterova 14,
Canada Clinical Trials Group. Concomitant and adjuvant temozolo- 11000 Belgrade, Serbia
mide and radiotherapy for newly diagnosed glioblastoma multiforme.
New Engl J Med 2005; 352: 987–996.
5. Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the Approved by the ESMO Guidelines Task Force: December 2004.
predictive value of O-6-methylguanine-DNA methyltransferase pro-
moter methylation in glioblastoma patients treated with temozolo- Correspondence to:
mide. Clin Cancer Res 2004; 10: 1871–1874. ESMO Guidelines Task Force
6. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local che- ESMO Head Office
motherapy with biodegradable carmustine (BCNU) wafers (Gliadel Via La Santa 7
wafers) in patients with primary malignant glioma. Neuro-oncol 2003; CH-6962 Lugano
5: 79–88. Switzerland